ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Nephrology

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,025Medicare Part D Prescriptions Filled, Including Refills

Rank: 24 out of 749

$1.25M Total Retail Price of All Prescriptions

Rank: 16 out of 749

545 Patients Receiving at Least One Drug in Part D
81%Patients 65 Years and Older
77% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in California
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

3% of this provider’s 545 patients filled at least one prescription for a schedule three drug, compared to an average of 6%.

Risky Drugs to Seniors

2% of this provider’s 8,307 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

41% of this provider’s prescriptions were for brand-name drugs, compared to an average of 31%.

Prescription Price

$114 was the average price of a prescription from this provider, compared to $116 among peers.

Prescriptions per Patient

20 is the average number of prescriptions (including refills) per patient, compared to an average of 14.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in California
ALLOPURINOL 639 558 1 10
AMLODIPINE BESYLATE 559 418 2 1
DIOVAN 420 345 3 14
CALCIUM ACETATE 408 293 10 4 16
RENVELA 393 225 5 3
LOSARTAN POTASSIUM 313 227 6 9
PROSOL 215 179 7 48
NIFEDIPINE ER 209 149 8 21
CARVEDILOL 199 138 9 11
METOPROLOL SUCCINATE 192 119 10 26
TAMSULOSIN HCL 191 184 11 29
SIMVASTATIN 186 169 12 5
FUROSEMIDE 183 153 13 2
PREDNISONE 174 125 14 28
SENSIPAR 167 52 15 8
OMEPRAZOLE 157 99 16 6
METOPROLOL TARTRATE 155 95 17 7
ULORIC 154 141 18 72
LISINOPRIL 142 126 19 4
PROCRIT 138 134 20 66
ATORVASTATIN CALCIUM 135 107 21 18
PANTOPRAZOLE SODIUM 132 104 22 30
CLONIDINE HCL 126 59 23 15
ZOLPIDEM TARTRATE 114 61 24 24
METFORMIN HCL 113 101 25 22
LEVOTHYROXINE SODIUM 110 63 26 13
FAMOTIDINE 107 69 27 35
RENAGEL 101 51 28 50
JANUVIA 99 91 29 33
NEXIUM 97 73 30 34
GLIPIZIDE 94 77 31 32
POTASSIUM CHLORIDE 92 64 32 37
ATENOLOL 91 62 33 20
HYDRALAZINE HCL 91 75 33 19
GABAPENTIN 90 67 35 25
COLCRYS 88 82 36 107
ISOSORBIDE MONONITRATE ER 86 73 37 45
MINOXIDIL 85 51 38 59
LOVAZA 78 70 39 51
SPS 76 67 40 198
FOSRENOL 74 11 41 76
NATEGLINIDE 73 59 42 153
MEGESTROL ACETATE 73 65 R 42 69
TRIAMCINOLONE ACETONIDE 72 65 44 85
GLIMEPIRIDE 71 70 45 61
LABETALOL HCL 64 25 46 45
MYCOPHENOLATE MOFETIL 61 50 47 170
SPIRONOLACTONE 58 58 48 44
CLOPIDOGREL 56 37 49 42
PRAVASTATIN SODIUM 54 33 50 49
WARFARIN SODIUM 53 45 51 31
AZITHROMYCIN 53 31 51 65
LIDODERM 51 41 53 57
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 20, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.